PubRank

F E Preston

Author PubWeight™ 196.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet 1994 3.56
2 Identity of viridans streptococci isolated from cases of infective endocarditis. J Med Microbiol 1993 3.36
3 Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990 2.44
4 Cerebral intravascular coagulation in diabetic ketoacidosis. Lancet 1974 2.35
5 Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet 1985 2.26
6 Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998 2.20
7 Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997 2.19
8 Essential thrombocythaemia and peripheral gangrene. Br Med J 1974 2.18
9 Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999 2.15
10 Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005 2.13
11 The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996 1.76
12 Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998 1.71
13 Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet 1990 1.69
14 Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980 1.68
15 Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Steering Committee of the UK National External Quality Assessment Scheme in Blood Coagulation. Thromb Haemost 1994 1.67
16 Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990 1.64
17 Thrombocytosis, circulating platelet aggregates, and neurological dysfunction. Br Med J 1979 1.59
18 Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995 1.59
19 Percutaneous liver biopsy and chronic liver disease in haemophiliacs. Lancet 1978 1.53
20 Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004 1.44
21 Hyposplenism in inflammatory bowel disease. Gut 1978 1.36
22 High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994 1.29
23 Cellular hyperviscosity as a cause of neurological symptoms in leukaemia. Br Med J 1978 1.27
24 Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med 1981 1.22
25 The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985 1.22
26 Progressive liver disease in haemophilia: an understated problem? Lancet 1985 1.19
27 A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991 1.19
28 Platelet abnormalities in diabetic peripheral neuropathy. Lancet 1975 1.18
29 Intravascular coagulation and E. coli septicaemia. J Clin Pathol 1973 1.18
30 A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001 1.17
31 Hyposplenism in ulcerative colitis. Lancet 1974 1.15
32 Evidence against vitamin K deficiency in normal neonates. Thromb Haemost 1980 1.13
33 Cerebral involvement with disseminated intravascular coagulation in intestinal disease. J Clin Pathol 1977 1.09
34 The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988 1.07
35 Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases. Br J Haematol 1983 1.07
36 Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987 1.07
37 Audit of oral anticoagulant treatment. The BCSH Haemostasis and Thrombosis Task Force of the British Society for Haematology. J Clin Pathol 1993 1.06
38 Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003 1.06
39 Disseminated intravascular coagulation as a consequence of cerebral damage. J Neurol Neurosurg Psychiatry 1974 1.06
40 Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol 1986 1.04
41 Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998 1.04
42 Elevated beta-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet 1978 1.03
43 A reassessment of vascular factors in relation to intravascular coagulation. Diabetologia 1976 1.02
44 Relationship between splenic size and splenic function. Gut 1978 1.02
45 Microvascular thrombosis of the bowel in paroxysmal nocturnal haemoglobinuria. J Clin Pathol 1987 1.02
46 Mesenteric infarction due to combined protein C deficiency and prothrombin 20210 defects. Postgrad Med J 1999 1.01
47 The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers. Atherosclerosis 1985 1.01
48 Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta 1979 0.99
49 HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997 0.99
50 Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 1977 0.99
51 Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 1982 0.99
52 Essential thrombocythaemia. Lancet 1982 0.97
53 Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost 1998 0.97
54 Severe disseminated intravascular coagulation associated with massive ventricular mural thrombus following acute myocardial infarction. Postgrad Med J 1988 0.97
55 Tentative protocol for the evaluation of coagulometers, based on one-stage prothrombin time. Clin Lab Haematol 1981 0.97
56 Disseminated intravascular coagulation. Br J Hosp Med 1982 0.97
57 Myelomatosis and the hyperviscosity syndrome. Br J Haematol 1978 0.95
58 Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage? Diabetologia 1987 0.95
59 Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man. Thromb Res 1982 0.95
60 Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 1994 0.94
61 Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997 0.94
62 Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000 0.94
63 Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation. Br J Haematol 1978 0.93
64 Association between necropsy evidence of disseminated intravascular coagulation and coagulation variables before death in patients in intensive care units. J Clin Pathol 1988 0.93
65 Serial changes in the coagulation system following clotting factor concentrate infusion. Thromb Diath Haemorrh 1975 0.92
66 Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 1997 0.92
67 Postpartum purpura fulminans: successful management with streptokinase. Br Med J 1973 0.92
68 Detection by PCR of hepatitis C virus in factor VIII concentrates. Lancet 1990 0.91
69 Oral methionine loading as a cause of acute serum folate deficiency: its relevance to parenteral nutrition. Postgrad Med J 1978 0.91
70 The hypercoagulable state in clinical practice. Br J Haematol 1991 0.91
71 Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997 0.90
72 Bleeding time in patients with hepatic cirrhosis. BMJ 1990 0.90
73 The role of immunoglobulin G and fibrinogen in platelet aggregation by Streptococcus sanguis. Br J Haematol 1997 0.90
74 A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. Br J Haematol 1999 0.90
75 Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels? Br J Haematol 1997 0.90
76 Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol 1989 0.90
77 Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood 1996 0.89
78 Platelet aggregation by oral streptococci. FEMS Microbiol Lett 1990 0.89
79 Evidence for the involvement of complement proteins in platelet aggregation by Streptococcus sanguis NCTC 7863. Br J Haematol 1996 0.89
80 The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. Br J Clin Pharmacol 1984 0.89
81 A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990 0.88
82 Proceedings: Abnormalities of splenic function in ulcerative colitis and Crohn's disease. Gut 1975 0.88
83 Effects of dietary fish oil supplementation on the fatty acid composition of the human platelet membrane: demonstration of selectivity in the incorporation of eicosapentaenoic acid into membrane phospholipid pools. Clin Sci (Lond) 1985 0.87
84 Platelet aggregation in patients with peripheral vascular disease. Atherosclerosis 1978 0.86
85 Acute hereditary tyrosinaemia type I: clinical, biochemical and haematological studies in twins. J Inherit Metab Dis 1981 0.86
86 Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemost 1984 0.86
87 Recurrent multiple-branch retinal arteriolar occlusions in a patient with protein C deficiency. Graefes Arch Clin Exp Ophthalmol 1989 0.86
88 Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004 0.86
89 Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies. Clin Lab Haematol 1998 0.86
90 Plasma 6-keto-prostaglandin F1alpha: fact or fiction. Thromb Res 1982 0.85
91 Coagulation disturbances following ascites recirculation. J Hepatol 1990 0.85
92 Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993 0.85
93 Mode of action of dipyridamole on human platelets. Thromb Res 1979 0.85
94 Beneficial effect of fish oil on blood viscosity in peripheral vascular disease. Br Med J (Clin Res Ed) 1984 0.85
95 Intravascular coagulation and renal failure in E. coli septicaemia. J Clin Pathol 1972 0.85
96 Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone 1987 0.84
97 Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease. Gut 1993 0.84
98 Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990 0.84
99 The effects of phenothiazines on human erythrocytes: an ultrastructural study. Br J Haematol 1971 0.84
100 Gangrene of the toes with palpable peripheral pulses. Ann Surg 1981 0.83
101 Non-A, non-B hepatitis and heat-treated factor VIII concentrates. Lancet 1985 0.83
102 Chronic liver disease in haemophiliacs. Br J Haematol 1990 0.82
103 Mechanisms of platelet aggregation by Streptococcus sanguis, a causative organism in infective endocarditis. Br J Haematol 1993 0.82
104 In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997 0.82
105 The kidney and intravascular coagulation in myelomatosis. Br Med J 1974 0.82
106 Acquired Glanzmann's thrombasthenia. Blood 1983 0.82
107 The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol 1983 0.82
108 An electron-microscope study of bacteria in two cases of Whipple's disease. J Pathol 1970 0.81
109 Acute renal failure in myelomatosis from intravascular coagulation. Br Med J 1972 0.81
110 Cortical and vascular prostaglandin synthesis during renal allograft rejection in the rat. Transplantation 1987 0.81
111 Intestinal disaccharidase activity in psoriatic enteropathy. Scand J Gastroenterol 1971 0.81
112 A comparison of the allelic frequencies of ten DNA polymorphisms associated with factor VIII and factor IX genes in Thai and Western European populations. Blood Coagul Fibrinolysis 1994 0.81
113 Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 1986 0.81
114 Reduced risk of non-A, non-B hepatitis after a first exposure to 'wet heated' factor VIII concentrate. Br J Haematol 1987 0.81
115 Increased soluble IL-2 receptor levels in HCV-infected haemophiliacs: a possible indicator of liver disease severity. Br J Haematol 1994 0.81
116 The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001 0.81
117 Protein C and protein S. Baillieres Clin Haematol 1989 0.80
118 Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996 0.80
119 The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994 0.80
120 A UK National External Quality Assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost 1999 0.80
121 Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency--partial/complete deletions and rearrangement of the antithrombin gene. Thromb Haemost 2000 0.80
122 The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1982 0.80
123 Aspirin, prostaglandins, and peripheral gangrene. Am J Med 1983 0.80
124 Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988 0.80
125 Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis. Br J Haematol 1989 0.80
126 The neutralisation of heparin by Trasylol. Thromb Res 1980 0.80
127 Predictive markers of chronic liver disease in hemophilia. Blood 1987 0.80
128 Electron microscope findings in the jejunal mucosa of patients with psoriasis. Arch Klin Exp Dermatol 1970 0.80
129 Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res 1977 0.80
130 The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996 0.79
131 The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol 1997 0.79
132 Thrombotic vascular disease. Br J Hosp Med 1985 0.79
133 Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993 0.79
134 Activated protein C resistance in homozygous sickle cell disease. Br J Haematol 1997 0.79
135 A new familial 'giant platelet syndrome' with structural, metabolic and functional abnormalities of platelets due to a primary megakaryocyte defect. Br J Haematol 1987 0.79
136 Hemolytic-uremic syndrome: demonstration of abnormalities of platelet reactivity and insensitivity to prostaglandin I2. Clin Nephrol 1985 0.79
137 Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994 0.79
138 Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of international normalised ratio: a thirty-three-laboratory collaborative study. The Steering Committee of the UK National External Quality Assessment Scheme for Blood Coagulation. Thromb Haemost 1996 0.79
139 Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate. Haemophilia 1999 0.79
140 Changes in haematological indices, blood viscosity and inhibitors of coagulation during treatment of endometriosis with danazol. Thromb Haemost 1994 0.78
141 Antibody-mediated tissue damage. Hyperviscosity and other complications of paraproteinaemia. J Clin Pathol Suppl (R Coll Pathol) 1979 0.78
142 Need for second-generation anti-HCV testing in haemophilia. Lancet 1992 0.78
143 Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol 1999 0.78
144 Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000 0.78
145 Disseminated intravascular coagulation with thymoma-associated Cushing's syndrome. Br Med J 1973 0.78
146 Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996 0.78
147 Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J Thromb Haemost 2003 0.78
148 Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984 0.78
149 A rapid and cost effective method for analysis of dinucleotide repeat polymorphisms in the factor VIII gene. Blood Coagul Fibrinolysis 1996 0.78
150 Lack of effect of a 24-hour infusion of iloprost in intermittent claudication. Thromb Res 1987 0.78
151 Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999 0.78
152 The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. Br J Haematol 1995 0.78
153 Computed tomography: qualitative and quantitative recognition of liver disease in haemophilia. J Comput Assist Tomogr 1983 0.78
154 Microangiopathic haemolytic anaemia: the phenomenon of red cell adherence. J Clin Pathol 1970 0.78
155 Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. Blood 1996 0.78
156 Mucosal plasminogen activator activity in peptic ulcer disease. Ann N Y Acad Sci 1992 0.77
157 Acute liver failure induced by alcohol and paracetamol in an HCV-infected haemophiliac. Br J Haematol 1998 0.77
158 Disorders of haemostasis in diabetes mellitus. Ric Clin Lab 1982 0.77
159 Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemost 1988 0.77
160 A study of the stimulation of human venous prostacyclin synthesis by dipyridamole. Thromb Res 1982 0.77
161 Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988 0.77
162 Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. Br J Haematol 2000 0.77
163 A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994 0.77
164 An evaluation and improvement program for inpatient anticoagulant control. Thromb Haemost 1997 0.77
165 Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994 0.77
166 Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009 0.77
167 The routine measurement of platelet volume: a comparison of aperture-impedance and flow cytometric systems. Clin Lab Haematol 1985 0.77
168 Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost 2004 0.76
169 Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001 0.76
170 Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis 1996 0.76
171 A placebo-controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina pectoris. Curr Med Res Opin 1990 0.76
172 Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991 0.76
173 Relationships between haemostatic factors and capillary morphology in human diabetic neuropathy. Thromb Haemost 1992 0.76
174 ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. BMJ 1997 0.76
175 A haemorrhagic platelet disorder associated with altered stimulus-response coupling and abnormal membrane phospholipid composition. Br J Haematol 1994 0.76
176 Point of care testing by health care professionals: current practice amongst the UK National External Quality Assessment Scheme Participants. Br J Haematol 2005 0.76
177 Antithrombin cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb Haemost 1998 0.76
178 Further evidence that activated protein C resistance affects protein C coagulant activity assays. Thromb Haemost 2000 0.76
179 Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme. Thromb Haemost 1998 0.76
180 Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. J Clin Pathol 1997 0.76
181 A novel mutation in intron K of the PROS1 gene causes aberrant RNA splicing and is a common cause of protein S deficiency in a UK thrombophilia cohort. Thromb Haemost 1998 0.76
182 Patient self-management of oral anticoagulation and external quality assessment procedures. Br J Haematol 2003 0.76
183 Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996 0.75
184 Massive cardiac disease in a patient with Waldenstrom's macroglobulinaemia. J Clin Pathol 1988 0.75
185 Familial antithrombin III deficiency and Mycoplasma pneumoniae pneumonia. J Clin Pathol 1991 0.75
186 Cumulative inhibitory effect of daily 40 mg aspirin on prostacyclin synthesis. Lancet 1981 0.75
187 Rebuttal to: oral contraceptives and venous thromboembolism. Thromb Haemost 2001 0.75
188 Liver biopsy in haemophilia. Br J Haematol 1997 0.75
189 Letter: Diabetic ketoacidosis presenting as neurosurgical emergencies. Br Med J 1974 0.75
190 Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis. J Clin Pathol 1988 0.75
191 Resistance to activated protein C. N Engl J Med 1994 0.75
192 Long-term management after splenectomy. Lifelong penicillin unproved in trials... BMJ 1994 0.75
193 Factor VII clotting assays: influence of thromboplastin. Thromb Haemost 1993 0.75
194 The platelet defect in acute myeloid leukaemia. J Clin Pathol 1984 0.75
195 Interferon alfa for chronic hepatitis C in haemophiliacs. Gut 1993 0.75
196 Non-surgical management of peripheral vascular disease. Br Med J (Clin Res Ed) 1981 0.75
197 Rapid assessment of haemophilia A carrier state by non-invasive techniques using the polymerase chain reaction. J Clin Pathol 1990 0.75
198 Neutralization of heparin by Trasylol. Ann Thorac Surg 1994 0.75
199 Between-centre agreement in homocysteine assays: experience from the UK NEQAS proficiency testing scheme. Thromb Haemost 2002 0.75
200 Interferon-alpha treatment and formation of factor VIII antibodies. Ann Intern Med 1997 0.75
201 The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 1984 0.75
202 Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal. J Thromb Haemost 2009 0.75
203 Effect of stanozolol on antithrombin III and protein C. Lancet 1983 0.75
204 Paralleling in conservative dentistry. 3. The pontostructor. Br Dent J 1967 0.75
205 Optimizing therapy with anticoagulants: risk analysis and socio-economic perspectives. Preface. Semin Thromb Hemost 1999 0.75
206 Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme. Haemophilia 1998 0.75
207 Effect of glucose on platelet thromboxane biosynthesis. Lancet 1979 0.75
208 DNA polymorphisms for carrier detection of hemophilia in Thailand. Southeast Asian J Trop Med Public Health 1995 0.75
209 Does HIV infection accelerate malignant transformation of pre-malignant states? Eur J Haematol 1992 0.75
210 Antiphospholipid antibody syndrome. J R Soc Med 1988 0.75
211 Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia. Thromb Haemost 1985 0.75
212 Haemorrhage and factor IX deficiency in pituitary insufficiency. Acta Haematol 1983 0.75
213 Fibrin in the kidney in myelomatosis. J Clin Pathol 1972 0.75
214 A method for the determination of activated factor VII using bovine and rabbit brain thromboplastins: demonstration of increased levels in disseminated intravascular coagulation. Thromb Res 1988 0.75
215 Proceedings: Essential thrombocythaemia and peripheral vascular disease. Br J Haematol 1974 0.75
216 Liver disease in haemophilia. Lancet 1985 0.75
217 Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. Thromb Res 1984 0.75
218 Mass in Vitreous in a Boy aged 5, ? Glioma. Proc R Soc Med 1927 0.75
219 Heparinised clotting factor concentrates in patients with Christmas disease and liver disease. Thromb Haemost 1977 0.75
220 Laboratory aspects of haemophilia therapy. Haemophilia 2002 0.75
221 Thromboxane and prostacyclin synthesis in experimental pancreas transplantation. Changes in parenchymal and vascular prostanoids. Transplantation 1993 0.75
222 Potential value of vintristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma. Eur J Haematol 1987 0.75
223 A common splice site mutation is shared by two families with different type 2N von Willebrand disease mutations. Thromb Haemost 1999 0.75
224 Local calibration of international normalised ratio improves between laboratory agreement: results from the UK National External Quality Assessment Scheme. UK NEQAS (Blood Coagulation) Steering Committee. Thromb Haemost 1999 0.75
225 Proceedings: Intravascular coagulation in the nervous system. J Clin Pathol 1975 0.75
226 Platelet suppressive therapy in clinical medicine. Br J Haematol 1985 0.75
227 MYOPIA AND PSEUDO-MYOPIA. Br J Ophthalmol 1947 0.75
228 Near-normal glycaemic control does not correct abnormal platelet reactivity in diabetes mellitus. Clin Sci (Lond) 1984 0.75
229 Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway. Clin Lab Haematol 2000 0.75
230 Colour-blindness in a Woman, aged 20. Proc R Soc Med 1931 0.75
231 Blood product concentrates and chronic live disease. Lancet 1982 0.75
232 Demonstration of abnormal factor VIII multimers in acquired von Willebrand's disease associated with a circulating inhibitor. Br J Haematol 1987 0.75
233 Changes in plasma osteocalcin concentration following treatment with stanozolol. Clin Chim Acta 1986 0.75
234 Platelet and vascular arachidonic acid metabolites: can they help detect a tendency towards thrombosis? Br J Haematol 1984 0.75
235 Mass in Vitreous in a Boy aged 5, ? Glioma. Proc R Soc Med 1927 0.75
236 A simple technique for studying immunoglobulin synthesis by normal and malignant plasma cells in vitro. J Immunol Methods 1977 0.75
237 Newer techniques in the study of hemostatic disorders. Semin Hematol 1978 0.75
238 Wet heating for safer factor VIII concentrate? Lancet 1985 0.75
239 Importance of Night-vision Tests. Br Med J 1942 0.75
240 Studies on the incorporation of eicosapentaenoic acid (EPA) into platelet membrane phospholipids and the effects of EPA supplementation on platelet function, skin bleeding time and blood viscosity in man. Br J Clin Pract Suppl 1984 0.75
241 Orbital plasmacytoma in established myeloma--a report of two cases. Clin Lab Haematol 1986 0.75
242 F.D.P. in glomerulonephritis. Br Med J 1971 0.75
243 Fibrinolysis in myelomatosis. Acta Haematol 1972 0.75
244 Surface ultramicroscopy of neonatal erythrocytes. Lancet 1970 0.75
245 Urinary thromboxane and 6-keto-prostaglandin F1 alpha are early markers of acute rejection in experimental pancreas transplantation. Transplantation 1994 0.75
246 Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000 0.75
247 DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. Thromb Haemost 1989 0.75
248 Intravascular coagulation and pre-eclamptic toxaemia. Lancet 1972 0.75
249 Norethisterone therapy for bleeding due to gastrointestinal telangiectases in Glanzmann's thrombasthenia. Br J Haematol 1998 0.75
250 Chronic hepatitis in haemophilia. Blood Rev 1993 0.75
251 von Willebrand factor/factor VIII binding is not affected by the Arg89Gln polymorphism in von Willebrand factor. Thromb Haemost 1996 0.75
252 Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B. Blood Coagul Fibrinolysis 1991 0.75
253 Platelet membrane glycoprotein abnormalities in myeloproliferative disease. Br J Haematol 1986 0.75
254 The effects of diet and insulin therapy on coagulation factor VII, blood viscosity, and platelet release proteins in diabetic patients with secondary sulphonylurea failure. Diabet Med 1991 0.75
255 An immunoradiometric assay for porcine factor VIII related antigen. Thromb Res 1981 0.75
256 Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance. Blood Coagul Fibrinolysis 1999 0.75
257 Dipyridamole and platelet function. Lancet 1978 0.75
258 Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group. Transfusion 1995 0.75
259 Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thromb Haemost 1996 0.75
260 Platelet function and coagulation in patients with hepatobiliary disorders receiving cefotetan prophylaxis. Infection 1988 0.75
261 Superficial Corneal Opacities. Proc R Soc Med 1934 0.75
262 Comparison of human and rabbit brain thromboplastin in evaluation of haemostatic defect of liver disease. Lancet 1987 0.75
263 A comparison of methods for the measurement of activated factor VII. Thromb Haemost 1992 0.75
264 GENESRCH: a computer program for restriction fragment analysis. Blood Coagul Fibrinolysis 1991 0.75
265 Improved diabetic control and platelet reactivity. Lancet 1985 0.75